Potential benefit of teprotumumab dose reduction to be discussed at AAO 2022
Adverse events, particularly hearing loss, in patients with thyroid eye disease (TED) treated with teprotumumab have been documented.
In a session at AAO 2021, Sears CM, et al said adverse events in patients with TED treated with teprotumumab are common but most are mild to moderate in severity, although they can cause some patients to interrupt or stop treatment.
In a 2022 observational case series, Sear CM, et al called for more studies to better understand the risk factors of potential for hearing loss in patients treated with teprotumumab for TED as well as baseline audiometry and ongoing monitoring.
At the upcoming AAO 2022, Ragini Phansalkar, PHD, BS, will present a case highlighting the potential to decrease these adverse effects with a dosage reduction of teprotumumab.
The session, Decrease of Teprotumumab-induced Hearing Loss with Comparable Efficacy Against TED using Dose Reduction, will be available On-Demand.